Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | KDR | P35968 | 4/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.33 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.30 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.30 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.30 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.30 |
| ▸ | STK10 | O94804 | 1/20 | 0.30 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.30 |
| ▸ | ABL1 | P00519 | 1/20 | 0.30 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | CSF1R | P07333 | 1/20 | 0.30 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
| ▸ | HCK | P08631 | 1/20 | 0.30 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.30 |
| ▸ | KIT | P10721 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL594407 | 0.75 | XDH (0.30) | XDH | |
| SCHEMBL29965599 | 0.75 | XDH (0.30) | XDH | |
| SCHEMBL595130 | 0.74 | KDM4E (0.35) | — | |
| SCHEMBL3635314 | 0.74 | TLR8 (0.33) | PDGFRBPDGFRA | |
| SCHEMBL29965036 | 0.73 | P2RX3 (0.37) | LMNAP2RX3P2RX2CYP3A4PDGFRB | |
| SCHEMBL15141851 | 0.73 | P2RX3 (0.37) | LMNAP2RX3P2RX2CYP3A4PDGFRB | |
| SCHEMBL765428 | 0.72 | LMNA (0.41) | LMNACYP2C19 | |
| SCHEMBL595924 | 0.72 | TDP1 (0.41) | — | |
| SCHEMBL594120 | 0.72 | PDE2A (0.30) | — | |
| SCHEMBL594921 | 0.71 | KDM4E (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114872-B2 | Triazolyl aminopyrimidine compounds | ELI LILLY AND COMPANY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY | 2010-05-27 | — | — | US | disclosed |
| EP-2155735-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2010-02-24 | — | — | EP | disclosed |
| WO-2008144222-A2 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | ELI LILLY AND COMPANY (US) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100130466-A1 | TRIAZOLYL AMINOPYRIMIDINE COMPOUNDS | DPYD, TP53, TYMP | LMNA 4572/4885CYP2C19 831/4885KDR 782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.